| | | 浙江东亚药业股份有限公司 关于可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 9 月 30 日，累计已有人民币 23,779,000 元 "东亚转债"转为公司 A 股普通股，累计转股股数为 1,154,021 股，占"东亚转 债"转股前公司已发行普通股股份总额的 1.0159%。 未转股可转债情况：截至 2025 年 9 月 30 日，尚未转股的"东亚转债" 金额为人民币 666,221,000 元，占"东亚转债"发行总量的比例为 96.5538%。 本季度转股情况：2025 年 7 月 1 日至 2025 年 9 月 30 日，共有 5,000 元 "东亚转债"转为公司 A 股普通股，转股股数为 245 股。 一、"东亚转债"发行上市概况 经上海证券交易所（以下简称"上交所"）自律监管决定书〔2023〕166 号 文同意，公司发行的 69,000 万元可转换公司债券于 2023 年 8 月 2 日起在上交所 挂牌交易，债券简称"东亚转 ...

Market Overview - The Shanghai Composite Index closed at 3853.44 points, above the annual line, with a gain of 0.83% [1] - The total trading volume of A-shares reached 1,894.457 billion yuan [1] Stocks Breaking Annual Line - A total of 153 A-shares have surpassed the annual line today, with notable stocks including Yunnan City Investment, Maiwei Co., and Dongsoft Zhaibo, showing significant deviation rates of 7.64%, 7.27%, and 5.57% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Jiuyuan Yinhai, Jida Communication, and Shanghai Jiubai [1] Top Stocks by Deviation Rate - Yunnan City Investment (600239) reported a daily increase of 10.16% with a deviation rate of 7.64% [1] - Maiwei Co. (300751) saw an 8.63% increase and a deviation rate of 7.27% [1] - Dongsoft Zhaibo (300183) increased by 5.91% with a deviation rate of 5.57% [1] Additional Notable Stocks - Nanjing Public Utilities (000421) increased by 5.03% with a deviation rate of 4.79% [1] - Suzhou High-tech (600736) rose by 4.86% with a deviation rate of 4.69% [1] - Other stocks with notable performance include Shunyu Co. (301519) and Leshi Xin (688631) with increases of 5.40% and 6.79% respectively [1]

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于举办2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 9 月 17 日 前 访 问 网 址 https://eseb.cn/1rrPgGezGGA 或使用微信扫描下方小程序码进行会前提问，浙江 东亚药业股份有限公司（以下简称"公司"或"东亚药业"）将通过本次业绩说 明会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 一、说明会类型 公司已于 2025 年 8 月 29 日在上海证券交易所网站（www.sse.com.cn）披露 了《2025 年半年度报告》及《2025 年半年度报告摘要》。为便于广大投资者更 加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2025 年 9 月 17 日（星 ...

Group 1 - The core viewpoint of the news is that Dongya Pharmaceutical (605177) reported significant declines in revenue and net profit for the first half of 2025, indicating financial distress and increased operational costs [1] - The total operating revenue for the first half of 2025 was 416 million yuan, a decrease of 35.85% year-on-year, while the net profit attributable to shareholders was -30.23 million yuan, down 193.09% [1] - The company's gross margin improved to 30.15%, an increase of 16.82% year-on-year, but the net margin fell to -7.28%, a decrease of 245.31% [1] Group 2 - The financial expenses, sales expenses, and management expenses collectively accounted for 20.95% of total revenue, reflecting a year-on-year increase of 58.36% [1] - The company’s cash flow situation is concerning, with operating cash flow per share at -2.07 yuan, a decrease of 93.53% year-on-year [1] - The company has a historical median ROIC of 8.14%, but the worst year recorded a ROIC of -3.87%, indicating poor investment returns [3] Group 3 - The company relies heavily on research and development for its business model, necessitating a thorough examination of the underlying drivers of this approach [3] - The company’s debt situation is alarming, with interest-bearing liabilities reaching 973 million yuan, an increase of 42.32% year-on-year [1] - The average operating cash flow over the past three years has been negative, raising concerns about the company's financial sustainability [3]

Summary of Key Points Core Viewpoint The report outlines the fundraising and usage status of the convertible bonds issued by Zhejiang Dongya Pharmaceutical Co., Ltd., detailing the total amount raised, its allocation, and the management of the funds. Group 1: Fundraising Details - The total amount raised from the convertible bonds is RMB 690 million, with a net amount of RMB 680.1844 million after deducting fees [1]. - The funds were fully received by July 12, 2023, and verified by an accounting firm [1]. Group 2: Fund Usage and Management - As of June 30, 2025, RMB 73.47 million has been used from the raised funds, with an investment income of RMB 0.399 million from financial products [1]. - The company has established four-party supervision agreements with banks and underwriters to ensure proper management of the raised funds [1]. - The balance of the funds in dedicated accounts is RMB 207.1073 million, which includes large deposits and structured deposits [1]. Group 3: Investment Projects - The company has not made any early investments or replacements with the raised funds during the reporting period [3]. - There are no instances of using idle funds to temporarily supplement working capital [5]. - The company plans to extend the timeline for the completion of two key projects to December 2025 due to various industry factors [4]. Group 4: Compliance and Reporting - The company has complied with all regulations regarding the disclosure of fundraising and usage, with no significant issues reported [4]. - There have been no changes to the investment projects funded by the convertible bonds during the reporting period [4].

Group 1 - The board of directors of Zhejiang Dongya Pharmaceutical Co., Ltd. held its tenth meeting of the fourth session, which was conducted both in-person and via communication methods [1][2] - All seven directors attended the meeting, and the meeting complied with relevant laws and regulations [1] - The board approved the proposal regarding the 2025 semi-annual report and its summary, which had been reviewed by the audit committee [1][2] Group 2 - The board also approved the special report on the storage and actual use of funds raised from the 2025 semi-annual convertible bonds, which was disclosed on the Shanghai Stock Exchange website [2] - The voting results for both proposals were unanimous, with 7 votes in favor and no votes against or abstentions [2]

Meeting Details - The fourth supervisory board meeting of Zhejiang Dongya Pharmaceutical Co., Ltd. was held on August 28, 2025, in Taizhou, Zhejiang Province, with all three supervisors present for voting [1][2] - The meeting was chaired by Ms. Xu Jing, and the convening and conducting of the meeting complied with relevant laws and regulations [1] Resolutions Passed - The supervisory board approved the proposal regarding the 2025 semi-annual report and its summary, affirming that the report is true, accurate, and complete [2] - The voting results for the semi-annual report were unanimous, with 3 votes in favor, 0 against, and 0 abstentions [2] - The board also approved the special report on the storage and actual use of funds raised from the 2025 semi-annual convertible bonds, with the same voting results [2]

Core Points - The company will not distribute profits or increase share capital from reserves for the first half of 2025 [3] - The board of directors and supervisory board confirm the authenticity, accuracy, and completeness of the report [1][5] - The half-year report has not been audited [2] Company Overview - The company is Zhejiang Dongya Pharmaceutical Co., Ltd. [6] - The fourth board meeting was held on August 28, 2025, with all directors present [6][8] - The supervisory board meeting also took place on the same day, with all supervisors present [13][16] Financial Data - The actual amount raised from the convertible bonds was RMB 69 million, with a net amount of RMB 68.018 million after deducting fees [21] - As of June 30, 2025, the company had invested RMB 29 million in financial products, with RMB 20 million remaining unexpired [25] Important Matters - The company has not experienced significant changes in its operating conditions during the reporting period [4] - The company has not changed its convertible bond fundraising investment projects during the reporting period [28] Asset Impairment - The company has recognized an asset impairment provision totaling RMB 32.0236 million for the first half of 2025 [38] - This includes a bad debt provision of RMB 0.0877 million for accounts receivable and a provision of RMB 31.9804 million for inventory [39][41] - The impairment provision is in accordance with accounting standards and reflects the company's asset situation accurately [42]

Core Viewpoint - East Asia Pharmaceutical's half-year report indicates a decline in revenue and profit due to industry challenges and competition, with a revenue of 416 million yuan and a net loss of 30.23 million yuan in the first half of 2025. However, the company is leveraging its strengths to explore market demand and expand its international market presence [2]. Group 1: Financial Performance - The company's revenue and profit have decreased in the first half of 2025, with revenue at 416 million yuan and a net loss of 30.23 million yuan [2]. - Despite short-term pressures, the company has identified several positive aspects in its business operations during the reporting period [2]. Group 2: Product Development and Sales Growth - The growth in sales of non-cephalosporin pharmaceutical intermediates and raw materials is a highlight, with revenue from this segment reaching 211 million yuan, a year-on-year increase of approximately 13% [3]. - The company holds over ten raw material drug approvals for non-cephalosporin products, including widely demanded varieties such as Etoposide and Levofloxacin [3]. Group 3: R&D Investment - The company invested 42.37 million yuan in R&D in the first half of 2025, accounting for 10.19% of its revenue, positioning it among the leaders in R&D intensity within the raw material drug industry [4]. - The company has submitted multiple registration applications for new raw materials, indicating a robust pipeline for future product offerings [4]. Group 4: International Market Expansion - The company is actively expanding its international market presence, having received the CEP certificate for its raw material drug, Cefaclor, from the European Medicines Agency, which is crucial for entering the European market [5]. - In the first half of 2025, the company achieved significant success in the South Korean market, with multiple products receiving registration [5]. Group 5: Strategic Milestones - The approval of the first formulation product, Levofloxacin tablets, marks a significant milestone in the company's integrated development strategy, enhancing its product line and competitive edge [7]. - The company is progressing with its capital projects funded by convertible bonds, which are expected to support future product registrations [7][8]. Group 6: Market Dynamics - The new national centralized procurement rules emphasize rational competition, which may benefit leading companies like East Asia Pharmaceutical by alleviating pricing pressures [8]. - The company's ongoing expansion into international markets, enhanced R&D capabilities, and integrated raw material and formulation development are expected to drive future growth [8].

Core Viewpoint - East Asia Pharmaceutical (605177) reported a decline in revenue and profit for the first half of 2025, with operating income of 416 million yuan and a net loss attributable to shareholders of 30.23 million yuan, due to adverse industry factors and competitive pressures [1] Group 1: Financial Performance - The company's revenue and profit have been under pressure, with a reported operating income of 416 million yuan and a net loss of 30.23 million yuan for the first half of 2025 [1] - Despite short-term challenges, the company has identified areas of improvement in its operations during the reporting period [1] Group 2: Product Development and Market Expansion - The growth in sales of non-cephalosporin pharmaceutical intermediates and raw materials is a highlight, with revenue from this segment reaching 211 million yuan, a year-on-year increase of approximately 13% [2] - The company holds over ten approval certificates for non-cephalosporin raw materials, including products with significant market demand [2] - The company has increased its market development efforts for non-cephalosporin products, with revenue from anticholinergic and synthetic antispasmodic drugs growing by 25.1% to 99.47 million yuan [2] Group 3: Research and Development - The company invested 42.37 million yuan in R&D, accounting for 10.19% of its operating income, with a strong overall R&D investment intensity in the raw material drug industry [3] - The company has submitted multiple registration applications for new raw materials, indicating a robust pipeline for future product offerings [3] Group 4: International Market Strategy - The company is actively expanding its international market presence, having received the CEP certificate for cephalexin raw materials, which allows entry into the European market [4] - The company has successfully registered several products in the South Korean market, indicating a growing number of approved products in overseas markets [4] Group 5: Regulatory and Competitive Landscape - The recent changes in national centralized procurement rules are expected to benefit leading companies in the industry, including East Asia Pharmaceutical, by alleviating price pressures [7] - The company is well-positioned to leverage its enhanced R&D capabilities and integrated raw material and formulation development strategy for future growth [7]